Welcome to our dedicated page for Alr Technologies news (Ticker: ALRTF), a resource for investors and traders seeking the latest updates and insights on Alr Technologies stock.
ALR Technologies SG Ltd (ALRTF) is a diabetes management and data management company whose news flow centers on developments in its human and animal health platforms. Company announcements highlight progress on the ALRT Diabetes Solution, which includes an FDA-cleared and HIPAA compliant diabetes management system, a Predictive A1C algorithm, and an FDA-cleared Insulin Dosing Adjustment program aimed at optimizing diabetes drug therapies.
A major focus of ALR Technologies’ recent news has been the GluCurve Pet CGM, a continuous glucose monitoring system developed for diabetic cats and dogs. Press releases describe internal manufacturing testing, independent non-inferiority study plans, and the scheduling of a relaunch into the Canadian market. The company also reports on manufacturing agreements with partners such as CGM Medical Technology Shenzhen Ltd and earlier agreements with Infinovo Medical Co. Ltd to secure CGM hardware supply for the animal health market.
Investors and observers following ALRTF can expect updates on topics such as product launches and relaunches for GluCurve Pet CGM in Canada and other regions, manufacturing capacity and hardware generations for CGM devices, distribution relationships with veterinary partners, and clinical study results related to the ALRT Diabetes Solution and Predictive A1C. The company also uses news releases to communicate about patent grants, licensing arrangements for its core algorithms, and participation in industry conferences and exhibitions.
This news page aggregates these company-issued updates so readers can review ALR Technologies’ latest disclosures on its diabetes management platforms, animal health initiatives, manufacturing arrangements, and regulatory and intellectual property milestones in one place.
ALR Technologies (OTC: ALRTF) announced the relaunch of the GluCurve Pet CGM in Canada in January 2026, with a planned U.S. rollout in early Q2 2026 and subsequent global expansion. The company completed internal manufacturing testing showing accuracy comparable to the leading veterinary blood glucose meter and has scheduled an independent non-inferiority study for mid-December. ALR estimates potential annual unit demand of 150,000–300,000 in Canada, 2,000,000–3,000,000 in the U.S., and 2,000,000–3,000,000 in Europe. Manufacturing is partnered with CGM Medical Technology Shenzhen at a Foxconn facility in Shenzhen. Canadian clinics will order from GluCurve.ca at relaunch.
ALR Technologies (OTCPK:ALRTF) has secured a Definitive Manufacturing Agreement with CGM Medical Technology Shen Zhen for the production of Continuous Glucose Monitor (CGM) hardware for its GluCurve Pet CGM system. The agreement grants ALRT exclusive global distribution rights in the animal health market.
The first commercial shipment is expected in Q3 2025. ALRT plans to establish a joint venture with CGM Medical to build an automated manufacturing facility in Singapore, pending successful sample testing and production thresholds. The company aims to expand its presence in both human and animal health diabetes markets, with potential investment and commercial opportunities under consideration.
Summary not available.
Summary not available.
Summary not available.
Covetrus will showcase its innovative technologies, including Pulse, the first cloud-based veterinary operating system, and the GluCurve Pet CGM, a continuous glucose monitoring system for diabetic pets, at VMX 2023 from January 14-18 in Orlando, Florida. Covetrus aims to address industry challenges through these offerings and will hold educational seminars focusing on practice management. The company also entered a co-branded distribution agreement with ALR Technologies SG Ltd (ALRTF) to enhance the availability of the GluCurve Pet CGM.
ALR Technologies SG Ltd. (OTCQB:ALRTF) has secured a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for distributing Continuous Glucose Monitor (CGM) hardware in the animal health market. This exclusive deal is expected to boost product availability and sales significantly in 2023. For December and Q4 2022, ALRT anticipates sales between $145,000 and $155,000, with Q1 2023 projected at $450,000 to $600,000. The company plans to increase production capacity and will showcase GluCurve at upcoming expos to enhance market visibility.